These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 29158272)

  • 1. Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus.
    Zheng X; Berti AD; McCrone S; Roch M; Rosato AE; Rose WE; Chen B
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus.
    Singh NB; Yim J; Jahanbakhsh S; Sakoulas G; Rybak MJ
    Diagn Microbiol Infect Dis; 2018 Aug; 91(4):363-370. PubMed ID: 29807674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Dilworth TJ; Leonard SN; Vilay AM; Mercier RC
    Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Roch M; Clair P; Renzoni A; Reverdy ME; Dauwalder O; Bes M; Martra A; Freydière AM; Laurent F; Reix P; Dumitrescu O; Vandenesch F
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5306-14. PubMed ID: 24957836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA.
    Tran N; Rybak MJ
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin.
    Srisrattakarn A; Chaiyapoke C; Booncharoen S; Wongthong S; Chanawong A; Tippayawat P; Tavichakorntrakool R; Lulitanond A
    Turk J Med Sci; 2021 Aug; 51(4):2150-2158. PubMed ID: 33705643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.
    Dilworth TJ; Sliwinski J; Ryan K; Dodd M; Mercier RC
    Antimicrob Agents Chemother; 2014; 58(2):1028-33. PubMed ID: 24277036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
    J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of synergy between beta-lactams and anti-methicillin-resistant Staphylococcus aureus agents from the standpoint of strain characteristics and binding action.
    Ono D; Yamaguchi T; Hamada M; Sonoda S; Sato A; Aoki K; Kajiwara C; Kimura S; Fujisaki M; Tojo H; Sasaki M; Murakami H; Kato K; Ishii Y; Tateda K
    J Infect Chemother; 2019 Apr; 25(4):273-280. PubMed ID: 30713034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro synergistic effects of various combinations of vancomycin and non-beta-lactams against Staphylococcus aureus with reduced susceptibility to vancomycin.
    Kang YR; Chung DR; Kim J; Baek JY; Kim SH; Ha YE; Kang CI; Peck KR; Song JH
    Diagn Microbiol Infect Dis; 2016 Nov; 86(3):293-299. PubMed ID: 27591174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insights.
    Kebriaei R; Rice SA; Singh NB; Stamper KC; Nguyen L; Sheikh Z; Rybak MJ
    J Antimicrob Chemother; 2020 Oct; 75(10):2894-2901. PubMed ID: 32591820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011.
    Hanaki H; Cui L; Ikeda-Dantsuji Y; Nakae T; Honda J; Yanagihara K; Takesue Y; Matsumoto T; Sunakawa K; Kaku M; Tomono K; Fukuchi K; Kusachi S; Mikamo H; Takata T; Otsuka Y; Nagura O; Fujitani S; Aoki Y; Yamaguchi Y; Tateda K; Kadota J; Kohno S; Niki Y
    J Infect Chemother; 2014 Sep; 20(9):527-34. PubMed ID: 25066429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effects of vancomycin and β-lactams against vancomycin highly resistant Staphylococcus aureus.
    Tabuchi F; Matsumoto Y; Ishii M; Tatsuno K; Okazaki M; Sato T; Moriya K; Sekimizu K
    J Antibiot (Tokyo); 2017 Jun; 70(6):771-774. PubMed ID: 28196977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
    Katayama Y; Murakami-Kuroda H; Cui L; Hiramatsu K
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3190-6. PubMed ID: 19451283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.
    Leonard SN; Supple ME; Gandhi RG; Patel MD
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2678-83. PubMed ID: 23545527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin.
    Aritaka N; Hanaki H; Cui L; Hiramatsu K
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1292-4. PubMed ID: 11257050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.